Tracazolate, a pyrazolopyridine, is an anxiolytic known to interact with ␥-aminobutyric acid (GABA) A receptors, adenosine receptors, and phosphodiesterases. Its anxiolytic effect is thought to be via its interaction with GABA A receptors. We now report the first detailed pharmacological study examining the effects of tracazolate on a range of recombinant GABA A receptors expressed in Xenopus laevis oocytes. Replacement of the ␥2s subunit within the ␣1␤3␥2s receptor with the ⑀ subunit caused a dramatic change in the functional response to tracazolate from potentiation to inhibition. The ␥2s subunit was not critical for potentiation because ␣1␤3 receptors were also potentiated by tracazolate. ␥2/⑀ chimeras revealed a critical Nterminal domain between amino acids 206 and 230 of ␥2, governing the nature of this response. Replacement of the ␤3 subunit with the ␤1 subunit within ␣1␤3␥2s and ␣1␤3⑀ receptors also revealed selectivity of tracazolate for ␤3-containing receptors, determined by asparagine at position 265 within transmembrane 2. Replacement of ␥2s with ␥1 or ␥3 revealed a profile intermediate to that of ␣1␤1⑀ and ␣1␤1␥2s. ␣1␤1␦ receptors were also potentiated by tracazolate; however, the maximum potentiation of the EC 20 was much greater than on ␣1␤1␥2. Concentration-response curves to GABA in the presence of tracazolate for ␣1␤1⑀ and ␣1␤1␥2s revealed a concentration-related decrease in maximum current amplitude, but a leftward shift in the EC 50 only on ␣1␤1␥2. Like ␣1␤1␥2s, GABA concentration-response curves on ␣1␤1␦ receptors were shifted to the left with increased maximum responses. Tracazolate has a unique pharmacological profile on recombinant GABA A receptors: its potency (EC 50 ) is influenced by the nature of the ␤ subunit; but more importantly, its intrinsic efficacy, potentiation, or inhibition is determined by the nature of the third subunit (␥1-3, ␦, or ⑀) within the receptor complex.
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The ␥-Aminobutyric acid type A (GABA A ) receptor is a major inhibitory neurotransmitter receptor in the vertebrate central nervous system. In most neurons, the binding of the neurotransmitter GABA to a GABA A receptor induces an inward Cl Ϫ current, which results in membrane hyperpolarization and reduced neuronal excitability. This ligand-gated ion channel is a heteromeric complex assembled from a number of different subunits (␣1-6, ␤1-4, ␥1-4, ␦, ⑀, , and ) (for reviews, see Barnard et al., 1998; Whiting, 1999) . Evidence suggests that in vivo GABA A receptors are pentameric complexes of ␣, ␤, and ␥ subunits with a stoichiometry of 2␣:2␤:1␥ (Chang et al., 1996; Farrar et al., 1999) . The stoichiometry of receptors containing ␦, ⑀, and is currently unknown, although evidence suggests that ␦ and ⑀ substitute for a ␥ subunit (Caruncho and Costa, 1994; Quirk et al., 1995; Whiting et al., 1997) , whereas replaces a ␤ subunit .
The GABA A receptor is allosterically modulated by a large number of compounds, including benzodiazepines; general anesthetic agents, such as halothane, barbiturates, and etomidate; and neuroactive steroids (Lambert et al., 1995; Sieghart, 1995; Whiting et al., 1995) . For a number of these compounds, studies with recombinant receptors have focused on defining receptor subtype selectivity, the amino acids involved in binding, and the mechanism of action. One chemical class of compounds, which is known to modulate GABA A receptors, that has received little attention in recent years is the pyrazolopyridines, which include tracazolate, etazolate, and cartazolate (Barnes et al., 1983) . Behavioral studies have shown that tracazolate and etazolate possess anxiolytic and anticonvulsant activity (Patel et al., 1985; Young et al., 1987) . Compared with the standard benzodiazepine chlordiazepoxide, tracazolate was 2 to 20 times less potent as an anxiolytic, but interestingly displayed a much larger window of separation between the anxiolytic effect and potential side effects (sedation, motor incoordination, and its interaction with ethanol and barbital) (Patel et al., 1985) .
Herein, we demonstrate that these compounds, particularly tracazolate, possess unique features, modulating these receptors in an allosteric manner previously undescribed, with dimetrically opposite actions on ␥2-and ⑀-containing receptors. In addition the generation of chimeric ␥2/⑀ subunits implicates the region equivalent to ␥2 residues 206 to 230 in determining the nature of this modulation.
Materials and Methods
Human GABA A Receptor cDNAs. The cloning and sequencing of human ␣1, ␣6, ␤1, ␤3, ␥1, ␥2s, ␥3, ␦, and ⑀ and the construction of the single point mutations ␤1S265N and ␤3N265S have been reported previously (Wingrove et al., , 1997 Thompson et al., 1997 Thompson et al., , 1999a Whiting et al., 1997, and references therein) .
Construction of Chimeric Subunits. Seventeen chimeric ␥2/⑀ subunits were constructed of which only the five most informative are described herein (Fig. 8) . Unique restriction endonuclease sites were introduced into the wild-type sequences by site-directed mutagenesis as described previously . Restriction fragments were gel-purified and ligated using standard techniques. The integrity of chimeric subunits was confirmed by DNA sequencing using an ABI 373 automated sequencer (Applied Biosystems, Foster City, CA).
Expression in Xenopus laevis Oocytes and Electrophysiological Recordings. Adult female X. laevis were anesthetized by immersion in a 0.1% solution of 3-aminobenzoic acid ethylester (pH adjusted to toad housing water with 1 M NaHCO 3 , pH 7.2-8.0) for 30 to 45 min. Ovary tissue was removed via a small abdominal incision and stage V and VI oocytes were isolated with fine forceps. After mild collagenase treatment to remove follicle cells (type IA, 0.5 mg/ml, for 6 min), the oocyte nuclei were directly injected with 10 to 20 nl of injection buffer (88 mM NaCl, 1 mM KCl, 15 mM HEPES, at pH 7, filtered through nitrocellulose) containing different combinations of human GABA A subunit cDNAs engineered into the expression vector pCDM8 or pcDNAI/Amp. The ratio of ␣:␤:␥2s constructs was generally 1:0.5:1, whereas the ratio for ␣:␤ was 1:1, for ␣:␤:␥3 was 1:1:1, for ␣:␤:␥1 was 1:1:10, and for ␣␤␦ and ␣␤⑀ was 1:0.5:3 with 1 corresponding to 6 ng/l of cDNA. Confirmation that all the subunits injected were being expressed was routinely checked using Zn 2ϩ , flunitrazepam, or picrotoxin. Oocytes were maintained at 19-20°C in modified Barth's solution (MBS) consisting of 88 mM NaCl, 1 mM KCl, 10 mM HEPES, 0.82 mM MgSO 4 , 0.33 mM Ca(NO 3 ) 2 , 0.91 mM CaCl 2 , 2.4 mM NaHCO 3 , at pH 7.5 supplemented with 50 g/ml gentamicin, 10 g/ml streptomycin, 10 units/ml penicillin, and 2 mM sodium pyruvate, for up to 6 days. For electrophysiological recordings, oocytes were placed in a 50-l bath and continually perfused at 4 to 6 ml/min with MBS. Cells were impaled with two 1-to 3-M⍀ electrodes containing 2 M KCl and voltage-clamped at Ϫ70 mV. In all experiments, drugs were applied in the perfusate until the peak of the response was observed. The magnitude of modulation of GABAevoked currents by allosteric modulators is critically dependent upon the concentration of GABA used (Parker et al., 1986; Wafford et al., 1994) . For this reason the modulatory effect of tracazolate was examined against an EC 20 concentration of GABA (range EC 18-25 ), which was determined for every individual oocyte. In all experiments, except those designed to investigate the direct effect of tracazolate, tracazolate was preapplied for 30 s before being coapplied with the appropriate concentration of GABA. To minimize the effect of receptor desensitization, agonist applications were separated by a period of at least 3 min upon recovery back to baseline. All data were expressed as either a percentage modulation of the GABA EC 20 value, or as a percentage of the maximal response to GABA. Curves were fitted using a nonlinear square-fitting program to the equation
, where x is the drug concentration, EC 50 is the concentration of drug eliciting a half-maximal response, and n H is the Hill coefficient. For some receptor subtypes high concentrations of tracazolate or etazolate (e.g., 100 M etazolate on ␣1␤3␥2s, and 30 M tracazolate on ␣6␤3␥2s) produced responses substantially smaller than the previous response. In these instances curves were fitted to the concentration before this point. Data are presented as the arithmetic mean Ϯ S.E.M. or geometric mean (ϪS.E.M., ϩS.E.M.) from a number (n) of different cells. Differences between means were evaluated by analysis of variance and Student's t test and considered significant if P Ͻ 0.05.
Solutions and Solvents. GABA 1 M stock was dissolved in MBS, ZnCl 2 1 M stock in 0.2 M HCl, and picrotoxin and tracazolate 100 mM stocks and flumazenil 10 mM stock in 100% dimethyl sulfoxide. The limit of solubility of tracazolate in MBS was 100 M. The maximum concentration of vehicle (0.1% dimethyl sulfoxide) was without effect. GABA, ZnCl 2 , picrotoxin, and tracazolate were obtained from Sigma Chemical (St. Louis, MO), whereas the Chemistry Department at Merck Sharp and Dohme (Harlow, Essex, UK) synthesized flumazenil.
Results
Potentiation of ␣1␤1␥2s and ␣1␤3␥2s GABA A Receptors: Selectivity for ␤3. GABA EC 20 responses on ␣1␤1␥2s and ␣1␤3␥2s receptors were potentiated in a concentrationdependent manner by tracazolate and etazolate (Table 1; Fig.  1 ). As stated above, on some receptor subtypes, high concentrations of tracazolate or etazolate produced responses substantially smaller than the previous response. These data points were not included in the curve fitting and to aid visualization of the data were omitted from the graphs. This decrease in apparent efficacy at high concentrations may be an artifact of the slow application time, inherent with the X. laevis oocyte system, which may allow receptor desensitiza- tion to occur during the rising phase of the inward current to GABA, resulting in a truncated response. Other explanations such as channel blockade, however, cannot be eliminated from the present data. The maximum potentiation (fitted to the ascending portion) ranged from between 168 and 315% and is comparable with that seen with both full benzodiazepine agonists and many other nonbenzodiazepine modulators of the GABA A receptor [e.g., loreclezole , pentobarbital (Thompson et al., 1996) , and neurosteroids (Lambert et al., 1995) ]. No significant direct activation by either tracazolate or etazolate was observed over the concentration range examined (30 nM-100 M). Interestingly, both compounds displayed a significant 6-to 9-fold selectivity for ␣1␤3␥2s over ␣1␤1␥2s receptors. Because structurally and functionally tracazolate and etazolate were similar, further investigations were performed with tracazolate only. ␤3 Selectivity Is Conferred by Asparagine 265. Selectivity for ␤2/3-containing GABA A receptors over ␤1 has previously been reported for loreclezole , ␤-carbolines (Stevenson et al., 1995) , etomidate (Hill-Venning et al., 1997) , furosemide (Thompson et al., 1999a) , and mefenamic acid (Halliwell et al., 1999) . For all these compounds this selectivity has been shown to be due to a critical asparagine residue at position 264 and 265 (numbering according to mature polypeptide sequence) within TM2 of the ␤2 and ␤3 subunit. It was logical therefore to see whether this residue also determined the ␤3 selectivity of tracazolate. The two mutant ␤ cDNAs (␤1Ser265Asn and ␤3Asn265Ser) were coexpressed with ␣1 and ␥2s and concentration-response curves to tracazolate constructed (Table 1 ; Fig. 2 ). Replacement of Ser265 within the ␤1 subunit with Asn (the ␤3 counterpart) increased the sensitivity of tracazolate, whereas the opposite mutation (Asn␤3 to Ser) decreased the sensitivity to tracazolate. Hence, the ␤3 selectivity of tracazolate is determined by asparagine 265 within the ␤3 subunit.
Interaction Is Not via Benzodiazepine Binding Site. Concentration-response curves to tracazolate were also constructed on oocytes expressing ␣1␤3 and ␣6␤3␥2s GABA A receptors (Table 1 ; Fig. 3 ). Similar to ␣1␤3␥2s receptors, control GABA EC 20 concentrations on ␣1␤3 and ␣6␤3␥2s receptors were potentiated by tracazolate. Statistical analysis (analysis of variance) revealed no significant differences in the log EC 50 , Hill coefficient, or maximum potentiation for ␣1␤3, ␣1␤3␥2s, or ␣6␤3␥2s. Unlike compounds that interact at the benzodiazepine site, receptors lacking a ␥ subunit were also potentiated by tracazolate. Replacement of the ␣1 subunit with an ␣6 subunit did not alter the concentration-response curve to tracazolate. Finally, 300 nM flumazenil, a benzodiazepine site antagonist, did not affect the degree of potentiation elicited by 10 M tracazolate on ␣1␤3␥2s receptors (198 Ϯ 42%, n ϭ 5 in the absence versus 223 Ϯ 31%, n ϭ 4 in the presence).
Tracazolate Inhibits ␣1␤1⑀ and ␣1␤3⑀ GABA A Receptors. In addition to replacing the ␣ and ␤ subunits, we studied the effects of replacing the ␥2 subunit. ⑀-Containing receptors reveal some unusual properties, including a proportion of constitutively active channels, fast desensitization kinetics, and a transient rebound current on GABA washout Neelands et al., 1999) . Unlike the receptor combinations mentioned above, on ␣1␤1⑀ and ␣1␤3⑀ receptors, tracazolate showed a significant direct effect, with low concentrations producing an inward current, whereas higher concentrations produced an inward current followed by an outward current (Fig. 4, A and B) . It has been shown previously that constitutively open channels can be modulated by certain allosteric modulators [e.g., ␤3 homomeric receptors (Wooltorton et al., 1997) ; ␣1␤2L259S␥2s ( Thompson et al., 1999b) ] and hence the effect of an allosteric modulator on the constitutively open channels and the GABAactivated channels can be difficult to separate. Further characterization of the direct effect of tracazolate on ␣1␤3⑀ receptors was undertaken in separate experiments. To enable direct comparison of the modulatory effect of tracazolate on ␥2-and ⑀-containing receptors, the application time of tracazolate before coapplication of tracazolate and GABA was kept at 30 s. To further facilitate comparison with the results obtained with ␣1␤3␥2s and ␣1␤1␥2s receptors, the inward current to GABA in the presence of tracazolate was normalized with respect to the response evoked by the control GABA EC 20 response (i.e., the effect of tracazolate on the constitutively open channels was omitted). As illustrated in Fig. 5A the direct effect of tracazolate could take up to 240 s to reach steady state, hence one caveat with the experimental design described above is the introduction of a small degree of error in the measurement of the inward current to GABA. Unlike its effects on ␣1␤3␥2, tracazolate caused inhibition of the control GABA EC 20 response ( Fig. 4; Table 2 ). The GABA response could be almost completely inhibited, and the IC 50 values for inhibition by tracazolate on ␣1␤⑀ receptors were similar to the EC 50 values obtained on ␣1␤␥2s receptors.
Outward Current to Tracazolate on ␣1␤3⑀ Receptors Is Carried by Cl ؊ Ions. Concentration-response curves to the direct effects of tracazolate were constructed on ␣1␤3⑀ receptors. As can be observed in Fig. 5A , a small inward current was observed followed by a larger outward current, which increased with increasing concentration up to a maximum response at 10 M. At high concentrations, the outward current took up to 240 s to reach a plateau followed by a washout period of up to 10 min to reestablish the baseline value; this was hypothesized to be due to block of constitutive activity. The outward current was measured using the peak of the inward current as the start value and normalized to the outward current induced by 100 M picrotoxin. Picrotoxin (10 M) has previously been shown to cause an 80 to 90% reduction in the holding current of oocytes expressing ␣1␤3⑀ receptors (Neelands et al., 1999) . The holding current of ␣1␤1⑀ and ␣1␤3⑀ receptors in the presence of 100 M picrotoxin is similar to that observed in uninjected oocytes (S. A. Thompson and K. A. Wafford, unpublished observations) , suggesting that 100 M picrotoxin blocks the majority of the constitutively active channels. In addition the baseline (holding current) upon washout of tracazolate was not completely reestablished. A gradual reduction of the holding current was also observed for oocytes expressing ␣1␤3⑀ receptors, which were voltage-clamped at Ϫ70 mV and left for 1 to 2 h (data not shown), suggesting a long-term shift in the leak current possibly due to chloride redistribution through the constitutively active channel. Interestingly, the IC 50 of the direct effect of tracazolate (i.e., inhibition of the constitutive activity) [1.4 (1.1, 1.6) M, n ϭ 4] was not significantly different from the IC 50 value for inhibition of a GABA-activated EC 20 response [1.2 (0.9, 1.5) M, n ϭ 4] (Fig. 5B) .
The current-voltage relationship was determined for the direct effect of 3 M tracazolate on ␣1␤3⑀ receptors. The data were best fitted to a linear regression (r 2 ϭ 0.94 Ϯ 0.02, n ϭ 4) and revealed a reversal potential of Ϫ25.7 Ϯ 1.3 mV, n ϭ 4, which was similar to the predicted reversal potential for Cl Ϫ ions of Ϫ25.4 mV in X. laevis oocytes with an external Cl Ϫ concentration of 89.91 mM (MBS used in this study) and an internal Cl Ϫ concentration of 33.4 mM (Barish, 1983) , indicating that the carrier of the direct effect is Cl Ϫ ions. Modulation of ␣1␤1␥1, ␣1␤1␥3, and ␣1␤1␦ Receptors. The opposing effects observed with tracazolate on ␥2s-and ⑀-containing receptors prompted studies on ␥1-, ␥3-, and ␦-containing receptors. These subunits were coexpressed with ␣1 and ␤1 subunits and concentration-response curves to tracazolate constructed. As can be seen in Fig. 6A tracazolate behaved GABA EC 20 responses for ␣1␤1␦ receptors were potentiated by tracazolate to levels substantially greater than that produced by a maximum GABA concentration (Fig. 6B) . Potentiation of a GABA EC 20 concentration by tracazolate above and beyond the maximum current elicited by GABA was not observed with any other subunit combination examined. The log EC 50 values and Hill coefficients, however, were not significantly different between ␣1␤1␦ and ␣1␤1␥2s.
Effect of Tracazolate on GABA Concentration-Response Curves. The studies mentioned above only examined the effect that various concentrations of tracazolate have on a single, low concentration of GABA (EC 20 ). To further understand the mechanism of action of tracazolate, its effect on a range of GABA concentrations was examined. GABA concentration-response curves were constructed in the absence and then the presence of a single concentration of tracazolate on oocytes expressing ␣1␤3⑀, ␣1␤3␥2s, and ␣1␤1␦ receptors.
On ␣1␤3␥2s receptors, 1 M tracazolate produced a significant (P Ͻ 0.05) 2.5 Ϯ 0.3-fold shift to the left of the GABA EC 50 with no significant effect on the maximum response or Hill coefficient (Fig. 7A ). Higher concentrations of tracazolate (10 and 30 M) further increased this leftward shift of the GABA concentration-response curve (21.6 Ϯ 5.5-and 39.3 Ϯ 15.8-fold, respectively). In addition the maximum response of GABA in the presence of 10 and 30 M tracazolate was significantly reduced compared with the maximum obtained for the control GABA concentration-response curve (67.6 Ϯ 4 and 40.0 Ϯ 2.9%, respectively). Tracazolate (30 M) also significantly reduced the Hill coefficient of the GABA concentration-response curve compared with the control (1.54 Ϯ 0.03 versus 0.98 Ϯ 0.14, P Ͻ 0.05).
For ␣1␤3⑀ receptors, the inward current alone to GABA and tracazolate was measured omitting any direct effect. The log EC 50 values and Hill coefficients for the control GABA concentration-response curves compared with those in the presence of 1 and 3 M tracazolate were not significantly different, whereas the maximum response obtainable to GABA in the presence of 1 and 3 M tracazolate were significantly lower (P Ͻ 0.05) (Fig. 7B) .
Similar to ␣1␤3␥2s receptors, concentration-response curves to GABA on ␣1␤1␦ receptors were shifted to the left by 10 and 30 M tracazolate (7.6 Ϯ 1.8-and 15.8 Ϯ 1.9-fold, respectively). However, unlike ␣1␤1␥2s the maximum response to GABA in the presence of 10 and 30 M tracazolate was significantly larger (202.9 Ϯ 27.7 and 305.1 Ϯ 34.2%, respectively) (Fig. 7C) . Domain 206 to 230 Determines Functional Response to Tracazolate. As described above, tracazolate is a positive modulator at receptors containing a ␥ subunit but a negative modulator when substituted by ⑀. To investigate the amino acid determinants of this effect, a series of chimeric ␥2/⑀ subunits were constructed, each having an N-terminal ␥2 domain. The junction between these two subunits was moved incrementally through to the start of TM2 from chimera C-A to C-D. The results from only the five most informative constructs are described previously (Fig. 8A) . Chimeric subunits were coexpressed with ␣1␤3 and tested for modulation of a GABA EC 20 response by 10 M tracazolate. Tracazolate (10 Fig. 7 . Concentration-response curves for GABA in the absence and presence of tracazolate on ␣1␤3␥2s, ␣1␤3⑀, and ␣1␤1␦. A, concentrationresponse curves for GABA (F), GABA ϩ 1 M tracazolate (f), GABA ϩ 10 M tracazolate (OE), and GABA ϩ 30 M tracazolate () on ␣1␤3␥2s receptors. B, concentration-response curves for GABA (F), GABA ϩ 1 M tracazolate (f), and GABA ϩ 3 M tracazolate (OE) on ␣1␤3⑀ receptors. C, concentration-response curves for GABA (F), GABA ϩ 10 M tracazolate (f), and GABA ϩ 30 M tracazolate (OE) on ␣1␤1␦ receptors. Data represent the mean Ϯ S.E.M. from the number of cells indicated from two or more batches of oocytes. M) was chosen because this concentration produced the greatest window of separation between the potentiation on ␣1␤3␥2s receptors and inhibition on ␣1␤3⑀ receptors. Similar to ␣1␤3⑀, chimera C-A and C-B were negatively modulated by tracazolate (␣1␤3⑀: Ϫ79.1 Ϯ 3.4%, n ϭ 6; ␣1␤3C-A: Ϫ46.4 Ϯ 8.1%, n ϭ 4; and ␣1␤3C-B: Ϫ80.4 Ϯ 6.6%, n ϭ 4). Conversely, chimeras C-C and C-D were positively modulated by tracazolate to levels not significantly different from ␣1␤3␥2s (␣1␤3C-C: 113 Ϯ 15%, n ϭ 4; ␣1␤3C-D: 88 Ϯ 6%, n ϭ 3; and ␣1␤3␥2s: 198 Ϯ 42%, n ϭ 5; Fig. 9 ). These results implicate a residue or residues within the ␥2 domain 206 to 230 that confer the functional response observed with tracazolate. However, replacement of this whole region in ␥2 with the homologous portion of ⑀ (chimera C-E) did not alter the functional response to tracazolate [i.e., positive modulation similar to that of ␣1␤3␥2 receptors (␣1␤3C-E: 210 Ϯ 51%, n ϭ 4; Fig. 9 )], suggesting that although this region may be necessary, other residues are also required to confer inhibition.
Discussion
Although tracazolate was first synthesized nearly 30 years ago, this is the first detailed electrophysiological study of its effects on recombinant GABA A receptors. Tracazolate binds to neither the benzodiazepine nor the GABA binding site but to another as-yet-unidentified site. Its potency (EC 50 ) is influenced by the nature of the ␤ subunit; more importantly, however, its intrinsic efficacy (i.e., whether it potentiates or inhibits GABA) is critically determined by the nature of the third subunit (␥1-3, ␦, or ⑀) within the receptor complex.
Tracazolate may prove to be a useful tool to aid identification of receptor subtypes within neuronal preparations.
Tracazolate Does Not Act via Benzodiazepine Binding Site. Tracazolate produced concentration-related potentiation of control GABA EC 20 responses on oocytes expressing the binary receptor ␣1␤3. This result is in contrast to benzodiazepine compounds, which, at relevant concentrations, do not modulate ␣␤ receptors (Levitan et al., 1988; Pritchett et al., 1988) . In addition, tracazolate did not displace [ The type of ␤ subunit present within the receptor complex has previously been shown not to effect the modulation obtained with benzodiazepine site ligands (Hadingham et al., 1993) . Tracazolate, however, was significantly more potent on ␣1␤3␥2s receptors compared with ␣1␤1␥2s receptors. Recently, an increasing number of structurally unrelated compounds have been identified that also show this selectivity (e.g., loreclezole, ␤-carbolines, etomidate, furosemide, and mefenamic acid). For each compound, this selectivity has been shown to be due to the presence of an asparagine residue at the homologous position 264 and 265 within TM2 of the ␤2 and ␤3 subunit, respectively. Similarly, this asparagine residue was shown to be responsible for the ␤3 selectivity observed with tracazolate. Collectively, these results demonstrate that tracazolate does not interact with the benzodiazepine site and are in agreement with the previous biochemical and electrophysiological data obtained for the pyrazolopyridines (Williams and Risley, 1979; Barnes et al., 1983) .
Importance of Third Subunit within Receptor Complex. The nature of the third subunit within the receptor complex was critical in determining the functional response to tracazolate. For ␣1␤1/3␥2s receptors tracazolate produced concentration-related potentiation of control GABA EC 20 responses; however, for ␣1␤1/3⑀ receptors GABA EC 20 responses were inhibited by tracazolate. Receptors containing a ␥1 or a ␥3 subunit produced an intermediate profile with low concentrations of tracazolate potentiating to a small degree the GABA EC 20 , whereas higher concentrations caused inhibition. These differing functional effects are in contrast to the general anesthetic agents such as pentobarbitone and propofol and the neuroactive steroids, which potentiate all the receptor subtypes examined herein Thompson et al., 1998; Maitra and Reynolds, 1999) . In addition, these agents are also dissimilar to tracazolate because they do not display ␤ subunit selectivity.
The largest degree of potentiation was observed with (Lees and Edwards, 1998) . One possible explanation of these results is that on ␣1␤1␦ receptors GABA behaves as a partial agonist with a low probability of opening. This probability of opening is increased in the presence of tracazolate or isoflurane, giving rise to a supramaximal response. Further evidence for GABA behaving as a partial agonist has been demonstrated using an Ltk Ϫ cell line stably expressing ␣4␤3␦ receptors in which concentration-response curves to 4,5,6,7-tetrahydroisoxazolo[5,4-c] pyridin-3-ol elicit significantly larger responses than GABA (Adkins et al., 2001; Brown et al., 2001) .
Outward Current to Tracazolate on ␣1␤3⑀ Receptors. Spontaneous channel openings in the absence of GABA have been demonstrated in outside-out patches pulled from fibroblasts transiently transfected with ␣1␤3⑀ (Neelands et al., 1999) . In addition to picrotoxin and tracazolate, Zn 2ϩ ions and bicuculline have been shown to elicit outward currents on ␣1␤3⑀ receptors (Neelands et al., 1999) . One explanation for the outward current observed with these agents is that they inhibit the constitutively active currents. Mutation of the 9Ј leucine residue within the ␤2 subunit and coexpression with ␣1␥2s produced a receptor with a high degree of constitutive activity, which, like ␣1␤3⑀ receptors, was reduced in the presence of picrotoxin, bicuculline, gabazine, and Zn 2ϩ (Thompson et al., 1999b ). Our results demonstrate that the outward current to tracazolate on ␣1␤3⑀ receptors is carried by chloride ions, suggesting that like other agents it inhibits constitutive activity. The small inward current to low concentrations of tracazolate may represent initial potentiation of the constitutive activity, which is then superseded by the outward current.
Differing Effects on GABA Concentration-Response Curves. Concentration-response curves to GABA in the absence and presence of tracazolate on ␣1␤3␥2s, ␣1␤3⑀, and ␣1␤1␦ receptors revealed further insights into the mechanism of action of tracazolate. GABA concentration-response curves on both ␣1␤3␥2s and ␣1␤1␦ receptors were shifted to the left with significantly lower EC 50 values. The maximum response to GABA, however, in the presence of increasing concentrations of tracazolate, were shifted in opposing directions; on ␣1␤3␥2s tracazolate reduced the maximum response to GABA, whereas on ␣1␤1␦ this was increased. The leftward shift in the GABA concentration-response curve with a reduction in the maximum response for ␣1␤3␥2s receptors is similar to that reported for loreclezole and SB-205384 (Meadows et al., 1997) and may indicate a common mechanism of action of these compounds. The similarities of these three compounds also extend to the selectivity for ␤2/3-containing receptors over ␤1-containing receptors. Benzodiazepine site ligands also produce a leftward shift in the GABA concentration-response curve; however, they cause no reduction in the maximum response (Sigel and Baur, 1988; Maksay et al., 2000) .
On ␣1␤3⑀ receptors tracazolate behaved as a noncompetitive antagonist, reducing the maximum response to GABA with no change in the log EC 50 value or Hill coefficients.
In conclusion, this study represents the first functional characterization of the modulatory effects of tracazolate on recombinant GABA A receptors and reveals that tracazolate has a unique profile unlike any other allosteric modulator characterized to date. Mutagenesis studies, aimed at identifying the molecular determinants responsible for the opposing functional effects of tracazolate on ␥-and ⑀-containing receptors have highlighted region 206 to 230 in ␥2 as being necessary but not sufficient in determining the different functional effects.
